Article ID Journal Published Year Pages File Type
6157045 American Journal of Kidney Diseases 2016 9 Pages PDF
Abstract
A substantial proportion of patients discontinue HHD therapy within the first 12 months of use of the modality. Patients with diabetes, substance use, nonlisting for kidney transplantation, and urban residence are at greater risk for discontinuation. Targeting high-risk patients for increased support from clinical teams is a potential strategy for reducing HHD therapy discontinuation and increasing technique survival.
Related Topics
Health Sciences Medicine and Dentistry Nephrology
Authors
, , , , , , , ,